<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02962310</url>
  </required_header>
  <id_info>
    <org_study_id>PK-09-045</org_study_id>
    <nct_id>NCT02962310</nct_id>
  </id_info>
  <brief_title>Bio Equivalence Study of Torrent Pharmaceutical Ltd's Rosuvastatin Calcium Tablets Under Fasting Condition.</brief_title>
  <official_title>An Open Label, Randomized, 2-Period, 2-Treatment,2-Sequence, Crossover, Single-Dose BE of Rosuvastatin Ca Tab 40 mg [Torrent,India] Versus Crestor 40 mg Tab [ AstraZeneca Pharmaceuticals LP, USA] in Healthy Subjects-Fasted Condition.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Torrent Pharmaceuticals Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Torrent Pharmaceuticals Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects to compare the single dose bioavailability of Torrent's Rosuvastatin Calcium Tablets
      40 mg and Crestor® 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA. Dosing periods of
      studies were separated by a washout period of 7 days.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An Open Label, Randomized, 2-period, 2- Treatment, 2-Sequence, Crossover, Single-dose
      Bioequivalence Study of Rosuvastatin Calcium Tablets containing Rosuvastatin Calcium 40 mg (
      Test Formulation, Torrent Pharmaceutical Ltd., India) Versus Crestor® 40 mg Tablets
      containing Rosuvastatin Calcium 40 mg (Reference , AstraZeneca Pharmaceuticals LP, USA) in
      Healthy Human Volunteers Under Fasting Condition.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Pre-dose to 96 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>Pre-dose to 96 hours post-dose</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Torrent Pharmaceutical Ltd's Rosuvastatin Calcium Tablets 40 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Crestor 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Torrent's Rosuvastatin Calcium Tablets 40 mg</intervention_name>
    <description>oral, crossover</description>
    <arm_group_label>Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crestor 40 mg Tablets of AstraZeneca LP, USA</intervention_name>
    <description>oral, crossover</description>
    <arm_group_label>Reference</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sex: male

          -  Age: 18-45 years

          -  Volunteer with BMI of 18-27 (inclusive both) kg/m2 with minimum of 50 kg weight.

          -  Healthy and willing to participate in the study.

          -  Volunteer willing to adhere to the protocol requirements and to provide written
             informed consent.

          -  Non-smokers or smoker who smokes less than 10 cigarettes per day.

        Exclusion Criteria:

          -  The volunteers were excluded from the study based on the following criteria:

          -  Clinically relevant abnormalities in the results of the laboratory screening
             evaluation.

          -  Clinically significant abnormal ECG or Chest X-ray.

          -  Systolic blood pressure less than 100 mm Hg or more than 140 mm Hg and diastolic blood
             pressure less than 60 mm Hg or more than 90 mm Hg.

          -  Pulse rate less than 50/minute or more than 100/minute. Oral temperature less than
             95°P or more than 98.6°P.

          -  Respiratory rate less than 12/minute or more than 20/minute

          -  History of allergy to the test drug or any drug chemically similar to the drug under
             investigation.

          -  History of alcohol or drug abuse

          -  Positive breath alcohol test

          -  Recent history of kidney or liver dysfunction.

          -  History of consumption of prescribed medication since last 14 days or OTC medication
             since last 07 days before beginning of the study.

          -  Volunteers suffering from any chronic illness such as arthritis, asthma etc.

          -  History of heart failure.

          -  HIV, HCV, HBsAg positive volunteers.

          -  Opiate, tetra hydrocannabinol, amphetamine, barbiturates, benzodiazepines, Cocaine
             positive volunteers based on urine test.

          -  Volunteers suffering from any psychiatric (acute or chronic) illness requiring
             medications.

          -  Administration of any study drug in the period 0 to 3 months before entry to the
             study.

          -  History of significant blood loss due to any reason, including blood donation in the
             past 3 months.

          -  History of pre-existing bleeding disorder.

          -  Existence of any surgical or medical condition, which, in the judgment of the chief
             investigator and/or clinical investigator/physician, might interfere with the
             absorption, distribution, metabolism or excretion of the drug or likely to compromise
             the safety of volunteers.

          -  Inability to communicate or co-operate due to language problem, poor mental
             development or impaired cerebral function.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2016</study_first_submitted>
  <study_first_submitted_qc>November 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2016</study_first_posted>
  <last_update_submitted>November 9, 2016</last_update_submitted>
  <last_update_submitted_qc>November 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

